The role of the urokinase receptor in epilepsy, in disorders of language, cognition, communication and behavior, and in the central nervous system

Current Pharmaceutical Design

Volumn 17, Issue 19, 2011, Pages 1914-1923

  Bruneau, Nadine ^a,b,c   Szepetowski, Pierre ^a,b,c  

^a INSERM   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c Turing Center for Living Systems CENTURI Aix Marseille University   (France)

Author keywords

Autism; Brain development; Cognition; Epilepsy; Language; PLAUR; Speech; SRPX2; Sushi domain; uPAR

Indexed keywords

PROTEIN; TRANSCRIPTION FACTOR FOXP2; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; X LINKED 2 SUSHI REPEAT PROTEIN;

ALZHEIMER DISEASE; ANXIETY; ARTICLE; AUTISM; BEHAVIOR DISORDER; BRAIN DEVELOPMENT; BRAIN MALARIA; BRAIN REGION; CELL TYPE; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; COMMUNICATION DISORDER; DOWN REGULATION; DYSPRAXIA; ENCEPHALITIS; EPILEPSY; EPILEPTOGENESIS; GENE CONTROL; GENE LOCATION; GENE MUTATION; HUMAN; INTERNEURON; LANGUAGE DISABILITY; LEUKOENCEPHALOPATHY; MICROGYRIA; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DOMAIN; ROLANDIC EPILEPSY; SEIZURE SUSCEPTIBILITY; SOCIAL INTERACTION; SPEECH DISORDER; STROKE; TRANSCRIPTION REGULATION; TRAUMATIC BRAIN INJURY;

ANIMALS; COGNITION DISORDERS; COMMUNICATION DISORDERS; EPILEPSY; HUMANS; LANGUAGE DISORDERS; MENTAL DISORDERS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR;

EID: 80051761931     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796718198     Document Type: Article

References (92)

1. Ragno P. The urokinase receptor: a ligand or a receptor? Story of a sociable molecule. Cell Mol Life Sci 2006; 63: 1028-1037.
2. Blasi F, Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 2010; 584: 1923-1930.
3. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010; 11: 23-36.
4. Huai Q, Mazar AP, Kuo A, et al. Structure of human urokinase plasminogen activator in complex with its receptor. Science 2006; 311: 656-659.
5. Archinti M, Britto M, Eden G, Furlan F, Murphy R, Degryse B. The urokinase receptor in the central nervous system. CNS Neurol Disord Drug Targets 2011; 10: 271-294.
6. Rudolf G, Valenti MP, Hirsch E, Szepetowski P. From rolandic epilepsy to continuous spike-and-waves during sleep and Landau-Kleffner syndromes: insights into possible genetic factors. Epilepsia. 2009; 50 Suppl 7: 25-28.
7. Huppke P, Kallenberg K, Gärtner J. Perisylvian polymicrogyria in Landau-Kleffner syndrome. Neurology 2005; 64: 1660.
8. De Tiège X, Goldman S, Verheulpen D, Aeby A, Poznanski N, Van Bogaert P. Coexistence of idiopathic rolandic epilepsy and CSWS in two families. Epilepsia 2006; 47: 1723-1727.
9. Deonna TW, Roulet E, Fontan D, Marcoz JP. Speech and oromotor deficits of epileptic origin in benign partial epilepsy of childhood with rolandic spikes (BPERS). Relationship to the acquired aphasia-epilepsy syndrome. Neuropediatrics 1993; 24: 83-87.
10. Scheffer IE. Autosomal dominant rolandic epilepsy with speech dyspraxia. Epileptic Disord 2000; Suppl 1: S19-S22.
11. Pal DK. Epilepsy and neurodevelopmental disorders of language. Curr Opin Neurol 2011. [Epub ahead of print]
12. Tuchman R. CSWS-related autistic regression versus autistic regression without CSWS. Epilepsia. 2009; 50 Suppl 7: 18-20.
13. Marín O, Rubenstein JL. Cell migration in the forebrain. Annu Rev Neurosci 2003; 26: 441-483.
14. Guerrini R, Dobyns WB, Barkovich AJ. Abnormal development of the human cerebral cortex: genetics, functional consequences and treatment options. Trends Neurosci 2008; 31: 154-162.
15. Powell EM, Mars WM, Levitt P. Hepatocyte growth factor/scatter factor is a motogen for interneurons migrating from the ventral to dorsal telencephalon. Neuron 2001; 30: 79-89.
16. Dewerchin M, Nuffelen AV, Wallays G, et al. Generation and characterization of urokinase receptor-deficient mice. J Clin Invest 1996; 97: 870-878.
17. Gyetko MR, Sud S, Kendall T, Fuller JA, Newstead MW, Standiford TJ. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J Immunol 2000; 165: 1513-1519.
18. Eagleson KL, Bonnin A, Levitt P. Region- and age-specific deficits in gamma-aminobutyric acidergic neuron development in the telencephalon of the uPAR(-/-) mouse. J Comp Neurol 2005; 489: 449-466.
19. Powell EM, Campbell DB, Stanwood GD, Davis C, Noebels JL, Levitt P. Genetic disruption of cortical interneuron development causes region- and GABA cell type-specific deficits, epilepsy, and behavioral dysfunction. J Neurosci 2003; 23: 622-631.
20. Wonders CP, Anderson SA. The origin and specification of cortical interneurons. Nat Rev Neurosci 2006; 7: 687-696.
21. Levitt P, Eagleson KL, Powell EM. Regulation of neocortical interneuron development and the implications for neurodevelopmental disorders. Trends Neurosci 2004; 27: 400-406.
22. Levitt P. Disruption of interneuron development. Epilepsia 2005; 46: 22-28.
23. Marín O, Valiente M, Ge X, Tsai LH. Guiding neuronal cell migrations. Cold Spring Harb Perspect Biol 2010; 2: a001834.
24. Bae MH, Bissonette GB, Mars WM, et al. Hepatocyte growth factor (HGF) modulates GABAergic inhibition and seizure susceptibility. Exp Neurol 2010; 221: 129-135.
25. Stumm RK, Zhou C, Ara T, et al. CXCR4 regulates interneuron migration in the developing neocortex. J Neurosci 2003; 23: 5123-5130.
26. Tiveron MC, Rossel M, Moepps B, et al. Molecular interaction between projection neuron precursors and invading interneurons via stromal-derived factor 1 (CXCL12)/CXCR4 signaling in the cortical subventricular zone/intermediate zone. J Neurosci. 2006; 26: 13273-13278.
27. Montuori N, Bifulco K, Carriero MV, et al. The cross-talk between the urokinase receptor and fMLP receptors regulates the activity of the CXCR4 chemokine receptor. Cell Mol Life Sci 2010 [Epub ahead of print] available from http://www.springerlink.com/content/e600g83v252u7r74/
28. Kato M, Dobyns WB. X-linked lissencephaly with abnormal genitalia as a tangential migration disorder causing intractable epilepsy: proposal for a new term, interneuronopathy. J Child Neurol 2005; 20: 392-397.
29. Yu FH, Mantegazza M, Westenbroek RE, Robbins CA, et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 2006; 9: 1142-1149.
30. Ogiwara I, Miyamoto H, Morita N, et al. Na(v)1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J Neurosci. 2007; 27: 5903-5914.
31. Martin MS, Dutt K, Papale LA et al. Altered function of the SCN1A voltage-gated sodium channel leads to gammaaminobutyric acid-ergic (GABAergic) interneuron abnormalities. J Biol Chem 2010; 285: 9823-9834.
32. Wang Y, Dye CA, Sohal V, et al. Dlx5 and Dlx6 regulate the development of parvalbumin-expressing cortical interneurons. J Neurosci 2010; 30: 5334-5345.
33. Hussman JP. Suppressed GABAergic inhibition as a common factor in suspected etiologies of autism. J Autism Dev Disord 2001; 31: 247-248.
34. Woo TU, Whitehead RE, Melchitzky DS, Lewis DA. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc Natl Acad Sci USA 1998; 95: 5341-5346.
35. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005; 6: 312-324.
36. Campbell DB, Li C, Sutcliffe JS, Persico AM, Levitt P. Genetic evidence implicating multiple genes in the MET receptor tyrosine kinase pathway in autism spectrum disorder. Autism Res 2008; 1: 159-168.
37. Lahtinen L, Huusko N, Myöhänen H, et al. Expression of urokinase-type plasminogen activator receptor is increased during epileptogenesis in the rat hippocampus. Neuroscience 2009; 163: 316-328.
38. Lahtinen L, Lukasiuk K, Pitkänen A. Increased expression and activity of urokinase-type plasminogen activator during epileptogenesis. Eur J Neurosci 2006; 24: 1935-1945.
39. Iyer AM, Zurolo E, Boer K, et al. Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies. Neuroscience 2010; 167: 929-945.
40. Liu B, Zhang B, Wang T, et al. Increased expression of urokinasetype plasminogen activator receptor in the frontal cortex of patients with intractable frontal lobe epilepsy. J Neurosci Res 2010; 88: 2747-2754.
41. Cunningham O, Campion S, Perry VH, et al. Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation. Glia 2009; 57: 1802-1814.
42. Beschorner R, Schluesener HJ, Nguyen TD, et al. Lesionassociated accumulation of uPAR/CD87- expressing infiltrating granulocytes, activated microglial cells/macrophages and upregulation by endothelial cells following TBI and FCI in humans. Neuropathol Appl Neurobiol 2000; 26: 522-527.
43. Gveric D, Hanemaaijer R, Newcombe J, van Lent NA, Sier CF, Cuzner ML. Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage. Brain 2001; 124: 1978-1988.
44. East E, Baker D, Pryce G, Lijnen HR, Cuzner ML, Gverić D. A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis. Am J Pathol 2005; 167: 545-554.
45. Deininger MH, Trautmann K, Magdolen V, Luther T, Schluesener HJ, Meyermann R. Cortical neurons of Creutzfeldt-Jakob disease patients express the urokinase-type plasminogen activator receptor. Neurosci Lett 2002; 324: 80-82.
46. Walker DG, Lue LF, Beach TG. Increased expression of the urokinase plasminogen-activator receptor in amyloid beta peptidetreated human brain microglia and in AD brains. Brain Res 2002; 926: 69-79.
47. Fauser S, Deininger MH, Kremsner PG, Magdolen V, Luther T, Meyermann R, Schluesener HJ. Lesion associated expression of urokinase-type plasminogen activator receptor (uPAR, CD87) in human cerebral malaria. J Neuroimmunol. 2000 Nov 1; 111(1-2): 234-240.
48. Sidenius N, Nebuloni M, Sala S, et al. Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease. J Neuroimmunol 2004; 157: 133-139.
49. Raghu H, Lakka SS, Gondi CS, et al. Suppression of uPA and uPAR attenuates angiogenin mediated angiogenesis in endothelial and glioblastoma cell lines. PLoS One 2010; 5: e12458.
50. Stubbs D, DeProto J, Nie K, et al. Neurovascular congruence during cerebral cortical development. Cereb Cortex. 2009; 19 Suppl 1: i32-i41.
51. Harrigan MR. Angiogenic factors in the central nervous system. Neurosurgery 2003; 53: 639-661.
52. Greenberg DA, Jin K. From angiogenesis to neuropathology. Nature 2005; 438: 954-959.
53. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251: 802-804.
54. Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 2005; 7: 436-451.
55. Royer-Zemmour B, Ponsole-Lenfant M, Gara H, et al. Epileptic and developmental disorders of the speech cortex: ligand/receptor interaction of wild-type and mutant SRPX2 with the plasminogen activator receptor uPAR. Hum Mol Genet 2008; 17: 3617-3630.
56. Miljkovic-Licina M, Hammel P, Garrido-Urbani S, Bradfield PF, Szepetowski P, Imhof BA. Sushi repeat protein X-linked 2, a novel mediator of angiogenesis. FASEB J 2009; 23: 4105-4116.
57. Roll P, Rudolf G, Pereira S, Royer B, et al. SRPX2 mutations in disorders of language cortex and cognition. Hum Mol Genet 2006; 15: 1195-1207.
58. Miwa JM, Stevens TR, King SL, et al. The prototoxin lynx1 acts on nicotinic acetylcholine receptors to balance neuronal activity and survival in vivo. Neuron 2006; 51: 587-600.
59. Morishita H, Miwa JM, Heintz N, Hensch TK. Lynx1, a cholinergic brake, limits plasticity in adult visual cortex. Science. 2010; 330: 1238-1240.
60. Chimienti F, Hogg RC, Plantard L, et al. Identification of SLURP-1 as an epidermal neuromodulator explains the clinical phenotype of Mal de Meleda. Hum Mol Genet 2003; 12: 3017-3024.
61. Tekinay AB, Nong Y, Miwa JM, et al. A role for LYNX2 in anxiety- related behavior. Proc Natl Acad Sci USA. 2009; 106: 4477-4482.
62. Darvas M, Morsch M, Racz I, Ahmadi S, Swandulla D, Zimmer A. Modulation of the Ca2+ conductance of nicotinic acetylcholine receptors by Lypd6. Eur Neuropsychopharmacol 2009; 19: 670-681.
63. Steinlein OK, Bertrand D. Nicotinic receptor channelopathies and epilepsy. Pflugers Arch. 2010; 460: 495-503.
64. Strug LJ, Clarke T, Chiang T, et al. Centrotemporal sharp wave EEG trait in rolandic epilepsy maps to Elongator Protein Complex 4 (ELP4). Eur J Hum Genet. 2009; 17: 1171-1181.
65. Scheffer IE, Jones L, Pozzebon M, Howell RA, Saling MM, Berkovic SF. Autosomal dominant rolandic epilepsy and speech dyspraxia: a new syndrome with anticipation. Ann Neurol. 1995; 38: 633-642.
66. Kugler SL, Bali B, Lieberman P, et al. An autosomal dominant genetically heterogeneous variant of rolandic epilepsy and speech disorder. Epilepsia 2008; 49: 1086-1090.
67. Michelucci R, Scudellaro E, Testoni S, et al. Familial epilepsy and developmental dysphasia: description of an Italian pedigree with autosomal dominant inheritance and screening of candidate loci. Epilepsy Res 2008; 80: 9-17.
68. Jenkins HT, Mark L, Ball G, et al. Human C4b-binding protein, structural basis for interaction with streptococcal M protein, a major bacterial virulence factor. J Biol Chem 2006; 281: 3690-3697.
69. Royer B, Soares DC, Barlow PN, et al. Molecular evolution of the human SRPX2 gene that causes brain disorders of the Rolandic and Sylvian speech areas. BMC Genet 2007; 8: 72-81.
70. Galtrey CM and Fawcett JW. The role of chondroitin sulfate proteoglycans in regeneration and plasticity in the central nervous system. Brain Res Rev 2007; 54: 1-18.
71. Gunnersen JM, Kim MH, Fuller SJ, et al. Sez-6 proteins affect dendritic arborization patterns and excitability of cortical pyramidal neurons. Neuron 2007; 56: 621-639.
72. Jacobson LH, Kelly PH, Bettler B, Kaupmann K, Cryan JF. GABA(B(1)) receptor isoforms differentially mediate the acquisition and extinction of aversive taste memories. J Neurosci 2006; 26: 8800-8803.
73. Vigot R, Barbieri S, Bräuner-Osborne H, Turecek R, et al. Differential compartmentalization and distinct functions of GABAB receptor variants. Neuron 2006; 50: 589-601.
74. Biermann B, Ivankova-Susankova K, Bradaia A, et al. The Sushi domains of GABAB receptors function as axonal targeting signals. J Neurosci 2010; 30: 1385-1394.
75. Gendrel M, Rapti G, Richmond JE, Bessereau JL. A secreted complement-control-related protein ensures acetylcholine receptor clustering. Nature. 2009; 461: 992-996.
76. Dityatev A, Fellin T. Extracellular matrix in plasticity and epileptogenesis. Neuron Glia Biol 2008; 4: 235-247.
77. Dityatev A, Seidenbecher CI, Schachner M. Compartmentalization from the outside: the extracellular matrix and functional microdomains in the brain. Trends Neurosci 2010; 33: 503-512.
78. Fisher SE, Scharff C. FOXP2 as a molecular window into speech and language. Trends Genet. 2009 Apr; 25(4): 166-177.
79. Roll P, Vernes SC, Bruneau N, et al. Molecular networks implicated in speech-related disorders: FOXP2 regulates the SRPX2/uPAR complex. Hum Mol Genet 2010; 19: 4848-4860.
80. Lai CS, Fisher SE, Hurst JA, Vargha-Khadem F, Monaco AP. A forkhead-domain gene is mutated in a severe speech and language disorder. Nature 2001; 413: 519-523.
81. Scerri TS, Brandler WM, Paracchini S, et al. PCSK6 is associated with handedness in individuals with dyslexia. Hum Mol Genet. 2011; 20: 608-614.
82. Reddi PP, Shore AN, Acharya KK, Herr JC. Transcriptional regulation of spermiogenesis: insights from the study of the gene encoding the acrosomal protein SP-10. J Reprod Immunol 2002; 53: 25-36.
83. Botto M, Kirschfink M, Macor P, Pickering MC, Würzner R, Tedesco F. Complement in human diseases: Lessons from complement deficiencies. Mol Immunol 2009; 46: 2774-2783.
84. Beigneux AP, Weinstein MM, Davies BS, Gin P, Bensadoun A, Fong LG, Young SG. GPIHBP1 and lipolysis: an update. Curr Opin Lipidol 2009; 20: 211-216.
85. Yu DH, Fan W, Liu G, et al. PHTS, a novel putative tumor suppressor, is involved in the transformation reversion of HeLaHF cells independently of the p53 pathway. Exp Cell Res 2006; 312: 865-876.
86. Paret C, Bourouba M, Beer A, et al. Ly6 family member C4.4A binds laminins 1 and 5, associates with galectin-3 and supports cell migration. Int J Cancer 2005; 115: 724-733.
87. Ni J, Lang Q, Bai M, et al. Cloning and characterization of a human LYPD7, a new member of the Ly-6 superfamily. Mol Biol Rep 2009; 36: 697-703.
88. Levitin F, Weiss M, Hahn Y, et al. PATE gene clusters code for multiple, secreted TFP/Ly-6/uPAR proteins that are expressed in reproductive and neuron-rich tissues and possess neuromodulatory activity. J Biol Chem 2008; 283: 16928-16939.
89. Study Group of Millennium Genome Project for Cancer, Sakamoto H, Yoshimura K, Saeki N, Katai H, et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet 2008; 40: 730-740.
90. Fischer J, Bouadjar B, Heilig R, et al. Mutations in the gene encoding SLURP-1 in Mal de Meleda. Hum Mol Genet 2001; 10: 875-880.
91. Shetty J, Wolkowicz MJ, Digilio LC, et al. SAMP14, a novel, acrosomal membrane-associated, glycosylphosphatidylinositolanchored member of the Ly-6/urokinase-type plasminogen activator receptor superfamily with a role in sperm-egg interaction. J Biol Chem 2003; 278: 30506-30515.
92. Yin L, Chung CM, Huo R, et al. A sperm GPI-anchored protein elicits sperm-cumulus cross-talk leading to the acrosome reaction. Cell Mol Life Sci 2009; 66: 900-908.